Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-10-23 Purchase |
2024-10-25 4:05 pm |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
10,000 | $7.9814 | $79,814 | 2,770,000 (Indirect) |
View |
| 2024-10-04 Purchase |
2024-10-08 6:34 pm |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
62,070 | $6.9943 | $434,137 | 82,070 (Indirect) |
View |
| 2024-09-10 Purchase |
2024-09-12 7:31 pm |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
107,500 | $4.6965 | $504,875 | 75,000 (Indirect) |
View |
| 2022-09-22 Purchase |
2022-09-23 10:58 am |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN Chief Executive Officer |
10,000 | $2.1042 | $21,042 | 1,064,940 (Indirect Direct) |
View |
| 2021-11-17 Sale |
2021-11-19 4:09 pm |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
25,000 | $4.6685 | $116,713 | 2,375,000 (Indirect) |
View |
| 2021-11-15 Sale |
2021-11-17 4:33 pm |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
15,438 | $4.8502 | $74,877 | 85,000 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-03 Option Award |
2025-01-06 4:23 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2025-01-03 Exercise |
2025-01-06 4:22 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
27,400 | $3.58 | 162,145 (Direct) |
View |
| 2025-01-03 Exercise |
2025-01-06 4:22 pm |
2021-03-12 2030-03-12 |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
102,400 | $0 | 162,145 (Direct) |
View |
| 2025-01-03 Exercise |
2025-01-06 4:22 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
50,000 | $3.78 | 162,145 (Direct) |
View |
| 2025-01-03 Exercise |
2025-01-06 4:22 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
25,000 | $3.47 | 162,145 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:21 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:20 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:18 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:18 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO |
179,473 | $0 | 179,473 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:16 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer |
64,497 | $0 | 64,497 (Direct) |
View |
| 2025-01-03 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-02 |
Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer |
64,497 | $0 | 64,497 (Direct) |
View |
Ownership |
2024-12-09 5:11 pm |
N/A 2027-12-01 |
Eton Pharmaceuticals Inc. | ETON | Erdogan-Trinkaus Ipek Chief Commercial Officer |
0 | $0 | 83,026 (Direct) |
View |
| 2024-10-02 Option Award |
2024-10-04 4:19 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer |
42,088 | $0 | 861,374 (Direct) |
View |
Ownership |
2024-09-12 4:05 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner |
0 | $0 | 2,672,500 (Indirect) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:21 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer |
144,677 | $0 | 374,763 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:19 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director |
30,000 | $0 | 133,133 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:19 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO |
438,633 | $0 | 2,473,014 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:18 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director |
30,000 | $0 | 164,555 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:17 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer |
144,677 | $0 | 813,430 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:16 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director |
30,000 | $0 | 164,555 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 4:15 pm |
N/A 2034-02-12 |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
30,000 | $0 | 164,555 (Direct) |
View |
Ownership |
2023-03-08 2:39 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer |
0 | $0 | 691,584 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director |
25,000 | $0 | 134,555 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
25,000 | $0 | 134,555 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director |
25,000 | $0 | 134,555 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO |
350,381 | $0 | 1,951,881 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director |
25,000 | $0 | 103,133 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-03 4:10 pm |
N/A 2033-02-19 |
Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer |
100,086 | $0 | 200,086 (Direct) |
View |
| 2022-07-12 Option Award |
2022-07-18 4:36 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN Chief Executive Officer |
110,000 | $0 | 110,000 (Direct) |
View |
| 2022-07-12 Option Award |
2022-07-18 4:32 pm |
N/A N/A |
Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
Ownership |
2022-04-14 4:05 pm |
N/A 2032-04-10 |
Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer |
0 | $0 | 100,000 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:39 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director |
50,000 | $0 | 78,133 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:36 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director |
50,000 | $0 | 109,555 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:34 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director |
50,000 | $0 | 109,555 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:32 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | Troutman William Wilson CFO and Secretary |
15,000 | $0 | 671,200 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:31 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director |
50,000 | $0 | 109,555 (Direct) |
View |
| 2022-02-07 Option Award |
2022-02-28 4:27 pm |
N/A 2032-02-07 |
Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO |
416,500 | $0 | 1,601,500 (Direct) |
View |